Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Advanced Leiomyosarcoma: early-phase trial registry
2 of 3 indexed Advanced Leiomyosarcoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Advanced Leiomyosarcoma: 3 US clinical trials tracked, 2 recruiting.
Advanced Leiomyosarcoma is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Washington University School of Medicine, running 1 of these trials.
Enrollment posture brief
Registry condition advanced-leiomyosarcoma
OPEN 2 | RECR 67% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Advanced Leiomyosarcoma lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Advanced Leiomyosarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Advanced Leiomyosarcoma is recruiting above its size-band peers.
2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
National Cancer Institute (NCI)
NCT06498648
Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Washington University School of Medicine
NCT06957431
Lurbinectedin + Doxorubicin In Leiomyosarcoma
Massachusetts General Hospital
NCT05099666
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Advanced Leiomyosarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Advanced Leiomyosarcoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Advanced Leiomyosarcoma page
3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Advanced Leiomyosarcoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Washington University School of Medicine sponsors the most Advanced Leiomyosarcoma trials on record, review their full trial history before evaluating a specific study. See Washington University School of Medicine's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Leiomyosarcoma condition card totals 3 registered trials; most-linked intervention Lurbinectedin; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.